Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus PALONOSETRON HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus PALONOSETRON HYDROCHLORIDE.
ALOXI vs PALONOSETRON HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Palonosetron is a selective serotonin 5-HT3 receptor antagonist with high binding affinity, inhibiting serotonin binding and preventing chemotherapy-induced nausea and vomiting. It also exhibits allosteric interactions and prolonged dissociation from the receptor, leading to a longer duration of action compared to other 5-HT3 antagonists.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
0.25 mg intravenously over 30 seconds, administered approximately 30 minutes before the start of chemotherapy; not to be repeated within 7 days.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 40 hours (range 30–60 hours), which supports once-daily dosing for chemotherapy-induced nausea and vomiting.
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Approximately 80% of the dose is excreted in urine (about 50% as unchanged drug) and 20% in feces.
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."